background
dec
china
report
cluster
case
pneumonia
peopl
wuhan
hubei
provinc
respons
pathogen
novel
coronaviru
name
sever
acut
respiratori
syndrom
coronaviru
report
relev
featur
first
case
europ
confirm
infect
name
coronaviru
diseas
first
patient
diagnos
diseas
jan
method
case
seri
follow
five
patient
admit
bichatclaud
bernard
univers
hospit
pari
franc
pellegrin
univers
hospit
bordeaux
franc
diagnos
semiquantit
rtpcr
nasopharyng
swab
assess
pattern
clinic
diseas
viral
load
differ
sampl
nasopharyng
blood
urin
stool
sampl
obtain
daili
day
hospit
admiss
everi
day
patient
discharg
sampl
refriger
ship
laboratori
rna
extract
realtim
rtpcr
viru
isol
titrat
procedur
done
patient
three
men
age
year
year
year
two
women
age
year
year
chines
origin
travel
franc
china
around
midjanuari
three
differ
clinic
evolut
describ
two
paucisymptomat
women
diagnos
within
day
exhibit
symptom
high
nasopharyng
titr
within
first
h
ill
onset
log
copi
per
cell
respect
viral
rna
detect
stool
twostep
diseas
progress
two
young
men
secondari
worsen
around
day
diseas
onset
despit
decreas
viral
load
nasopharyng
sampl
man
rapid
evolut
toward
multipl
organ
failur
persist
high
viral
load
lower
upper
respiratori
tract
system
viru
dissemin
viru
detect
plasma
patient
die
day
ill
feb
patient
recov
discharg
feb
interpret
illustr
three
differ
clinic
biolog
type
evolut
five
patient
infect
detail
comprehens
viral
sampl
strategi
believ
find
contribut
better
understand
natur
histori
diseas
contribut
advanc
implement
effici
infect
control
strategi
coronaviru
diseas
epidem
spread
within
china
secondarili
also
outsid
china
basic
reproduct
number
estim
mortal
rate
around
eu
european
econom
area
uk
march
case
report
franc
includ
death
seven
franc
far
sever
studi
describ
demograph
clinic
biolog
characterist
patient
radiolog
patholog
find
associ
specif
studi
report
common
symp
tom
incub
period
biolog
abnorm
radio
graphic
abnorm
ct
abnorm
treatment
data
addit
describ
vari
degre
ill
sever
mild
sever
critic
report
proport
complic
includ
acut
respiratori
distress
syndrom
case
fatal
rate
variabl
associ
complic
death
articl
detail
comprehens
sampl
strategi
report
clinic
biolog
featur
first
five
case
confirm
europ
occur
franc
dynam
parallel
chang
viral
load
base
sever
acut
respiratori
syndrom
coronaviru
rna
detect
case
seri
part
overal
french
clinic
cohort
assess
patient
patient
french
hospit
diagnos
accord
french
nation
health
agenc
criteria
enrol
cohort
jan
jan
togeth
french
nation
regulatori
author
french
ministri
health
jan
determin
indic
criteria
compassion
use
investig
antivir
treatment
remdesivir
sign
sever
ill
diagnosi
secondari
clinic
aggrav
respiratori
symptom
gener
sign
base
criteria
sever
pneumonia
caus
appendix
p
basi
expert
opinion
avail
data
januari
consid
remdesivir
might
best
potenti
drug
treatment
although
restrict
patient
sever
diseas
intraven
rout
load
dose
mg
mainten
daili
dose
mg
total
durat
day
criteria
discharg
total
recoveri
european
centr
diseas
prevent
control
guidelin
asymptomat
patient
two
rtpcr
neg
naso
pharyng
sampl
least
h
apart
five
patient
case
seri
differ
stage
infect
includ
two
patient
mild
diseas
admiss
secondari
worsen
result
admiss
intens
care
unit
icu
one
initi
sever
ill
patient
directli
admit
icu
acut
respiratori
failur
two
patient
mild
diseas
diagnos
earli
infect
use
openaccess
clinic
character
protocol
sever
emerg
infect
intern
sever
acut
respiratori
emerg
infect
consortium
support
updat
respons
studi
approv
french
ethic
committe
written
inform
consent
obtain
patient
involv
next
kin
evid
studi
search
pubm
central
studi
report
present
clinic
characterist
patient
coronaviru
diseas
use
term
clinic
clinic
databas
incept
feb
languag
restrict
appli
search
return
public
paper
describ
demograph
clinic
biolog
characterist
patient
radiolog
patholog
find
associ
particular
report
common
symptom
incub
period
biolog
abnorm
radiograph
abnorm
ct
abnorm
treatment
data
also
describ
vari
degre
ill
sever
mild
sever
critic
report
proport
complic
includ
acut
respiratori
distress
syndrom
case
fatal
rate
variabl
associ
complic
death
addit
studi
report
data
viru
shed
studi
particular
dynam
viral
load
sputum
urin
throat
swab
stool
sampl
symptomat
asymptomat
individu
also
evalu
viru
shed
patient
recov
studi
report
clinic
data
first
patient
diagnos
europ
studi
also
bring
field
new
origin
find
includ
patient
differ
stage
infect
ie
earli
stage
later
cours
diseas
detail
comprehens
sampl
strategi
patient
enrol
earli
contact
patient
enrol
later
cours
diseas
knowledg
associ
clinic
evolut
virolog
dynam
report
past
allow
us
describ
three
pattern
paucisymptomat
patient
diagnos
quickli
diseas
cours
earli
high
nasopharyng
shed
sever
acut
respiratori
syndrom
coronaviru
within
first
h
ill
onset
log
copi
per
cell
respect
patient
twostep
diseas
progress
secondari
worsen
around
day
diseas
onset
despit
decreas
viral
load
nasopharyng
sampl
patient
rapid
evolut
toward
multipl
organ
failur
persist
high
viral
load
lower
upper
respiratori
tract
system
viru
dissemin
viru
detect
plasma
ie
old
patient
paucisymptomat
patient
high
viral
load
upper
respiratori
tract
sampl
might
potenti
transmit
diseas
first
day
symptom
despit
mild
present
diseas
implic
control
measur
combin
immedi
isol
case
symptom
onset
togeth
rapid
screen
monitor
contact
infect
patient
patient
sever
diseas
two
pattern
identifi
first
pattern
biphas
evolut
start
mild
present
follow
secondari
respiratori
worsen
despit
decreas
viral
load
nasopharyng
sampl
suggest
lung
damag
phase
relat
immunopatholog
lesion
second
pattern
observ
sever
ill
patient
die
persist
high
viral
excret
upper
respiratori
tract
sampl
combin
posit
viru
detect
bodi
fluid
includ
blood
find
contribut
better
understand
natur
histori
diseas
tailor
treatment
strategi
see
onlin
appendix
clinic
sampl
diagnost
test
obtain
accord
guidelin
patient
sampl
strategi
implement
sampl
obtain
daili
day
hospit
admi
sion
subsequ
everi
day
patient
discharg
death
upper
lower
possibl
respiratori
tract
sampl
also
blood
urin
stool
sampl
rectal
swab
appropri
obtain
upper
respiratori
sampl
either
nasopharyng
aspir
nasopharyng
swab
sigma
virocult
medic
wire
instrument
corsham
uk
stool
sampl
either
faecal
swab
stool
blood
sampl
edta
tube
adapt
rtpcr
sampl
refriger
ship
laboratori
nation
refer
center
respiratori
virus
institut
pasteur
pari
hospic
civil
de
lyon
lyon
franc
procedur
rna
extract
realtim
rtpcr
rtrtpcr
viru
isol
titrat
undertaken
rna
extract
done
extract
nucleospin
dx
viru
kit
macherey
nagel
germani
autom
nuclisen
easymag
franc
use
manufactur
instruct
rdrp
quantit
rtrtpcr
appendix
p
use
detect
rdrp
rtpcr
correspond
protocol
sampl
respiratori
sampl
plasma
stool
posit
quantif
number
rna
copi
done
accord
scale
rang
copi
per
viral
load
stool
calcul
previous
describ
express
number
rna
copi
per
g
stool
qualiti
nasopharyng
swab
check
use
cell
control
rgene
kit
kit
provid
quantifi
plasmid
cellular
quantif
viral
load
respiratori
sampl
calcul
method
stool
normalis
accord
cellular
quantif
number
rna
copi
per
cell
posit
plasma
sampl
quantifi
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
studi
data
final
respons
decis
submit
public
main
clinic
biolog
characterist
five
patient
hospit
admiss
present
tabl
patient
patient
diagnos
day
hospit
admiss
patient
diagnos
day
fulfil
nation
health
agenc
case
definit
admiss
histori
travel
resid
citi
wuhan
feb
patient
except
patient
fulli
recov
discharg
patient
die
feb
schemat
present
major
event
case
present
figur
clinic
biolog
characterist
day
day
case
present
appendix
pp
patient
mild
diseas
admiss
secondarili
sever
diseas
follow
definit
chines
center
diseas
control
prevent
patient
chines
male
tourist
wuhan
admit
bichatclaud
bernard
univers
hospit
pari
franc
diagnos
jan
ill
day
day
arriv
pari
wife
patient
visit
hospit
wuhan
jan
gout
episod
influenzalik
symptom
tabl
jan
ill
day
admit
hospit
day
diagnosi
mild
lymphopenia
thrombopenia
abnorm
chest
xray
ill
day
transfer
icu
worsen
oxygen
satur
po
mm
hg
flow
nasal
cannula
lmin
bilater
lung
abnorm
includ
groundglass
opac
reticulonodular
syndrom
alveolar
opac
chest
ct
scan
appendix
p
load
dose
remdesivir
administ
jan
ill
day
follow
mainten
treatment
jan
discharg
back
infecti
diseas
ward
ill
day
remdesivir
treatment
discontinu
alanin
aminotransferas
elev
level
three
time
higher
upper
limit
normal
maculopapular
rash
without
anaphylaxi
eosinophilia
system
symptom
patient
screen
hepat
b
c
cytomegaloviru
epsteinbarr
viru
herp
simplex
viru
activ
infect
detect
skin
liver
abnor
maliti
decreas
within
day
patient
becam
asymptomat
follow
day
discharg
feb
patient
old
man
chines
origin
base
franc
travel
busi
china
flew
back
shanghai
franc
jan
report
specif
exposur
within
day
symptom
onset
except
stay
wuhan
arteri
hypertens
underli
diseas
influenzalik
symptom
start
jan
diagnos
jan
ill
day
pellegrin
univers
hospit
admit
hospit
ill
day
transfer
icu
fever
skin
mottl
suggest
sepsi
jan
ct
scan
show
bilater
lung
abnorm
includ
groundglass
opac
reticulonodular
syndrom
scarc
alveolar
opac
icu
load
dose
remdesivir
administ
jan
ill
day
follow
mainten
treatment
feb
full
recoveri
discharg
feb
patient
rapidli
progress
diseas
classifi
critic
diagnosi
patient
chines
male
tourist
yichang
hubei
provinc
china
diagnos
jan
ill
day
day
arriv
europ
howev
airborn
contact
precaut
observ
hospit
stay
diagnosi
jan
acut
respiratori
failur
trigger
icu
admiss
bichatclaud
bernard
univers
hospit
subsequ
develop
multipl
organ
failur
acut
respiratori
distress
syndrom
acut
kidney
injuri
liver
failur
sepsislik
shock
diagnosi
confirm
jan
transfer
refer
icu
bichatclaud
bernard
hospit
pari
broadspectrum
antibacteri
start
possibl
superinfect
remdesivir
start
load
dose
two
pathogen
identifi
suscept
acinetobact
baumannii
multiplex
pcr
confirm
tracheal
aspir
cultur
aspergillu
flavu
tracheal
aspir
cultur
antiinfect
treatment
adapt
treat
baumanii
meropenem
tigecyclin
colimycin
follow
meropenem
levofloxacin
initi
treat
flavu
voriconazol
switch
isavuconazol
voriconazol
remdesivir
contain
safeti
associ
evalu
yet
remdesivir
discon
tinu
jan
patient
need
renal
replac
therapi
ct
scan
jan
show
bilater
pleuropneumopathi
includ
pleural
effus
alveolar
condens
groundglass
opac
pulmonari
cyst
feb
sever
diseas
persist
viral
detect
riskbenefit
assess
consid
favour
remdesivir
reiniti
multipl
organ
failur
persist
despit
appropri
treatment
baumannii
flavu
superinfect
identifi
patient
die
feb
ill
day
patient
admit
hospit
earli
onset
symptom
classifi
mild
diseas
patient
patient
wife
chines
woman
diagnos
jan
bichatclaud
bernard
univers
hospit
ill
day
day
arriv
pari
spent
day
patient
moder
influenzalik
symptom
jan
ill
day
abnorm
chest
xray
day
persist
incapacit
cough
condit
improv
without
specif
treatment
becam
asymptomat
feb
ill
day
discharg
feb
patient
patient
daughter
chines
woman
diagnos
jan
ill
day
stay
patient
sinc
travel
china
mild
symptom
sore
throat
dri
cough
jan
ill
day
normal
chest
xray
cough
initi
mild
increas
transient
time
asymptomat
feb
ill
day
without
specif
treatment
discharg
feb
patient
nasopharyng
sampl
collect
within
first
h
ill
onset
allow
earli
diagnosi
earli
specimen
high
viral
load
enabl
wholegenom
viru
sequenc
viru
isol
tabl
maxim
normalis
viral
load
obtain
respiratori
specimen
log
copi
per
cell
patient
log
copi
per
cell
patient
base
rdrp
quantit
rtrtpcr
viral
load
respiratori
sampl
decreas
time
figur
detect
rtpcr
neg
ill
day
patient
ill
day
patient
figur
patient
also
posit
detect
stool
viral
load
high
log
copi
per
g
stool
patient
log
copi
per
g
stool
patient
howev
viru
detect
serum
urin
sampl
patient
nasopharyng
sampl
collect
ill
day
patient
day
posit
rtrtpcr
viral
load
log
copi
per
cell
detect
quantifi
viral
load
respect
wholegenom
viru
sequenc
obtain
direct
sequenc
patient
viru
isol
unsuccess
case
secondari
evolut
sever
diseas
two
patient
day
correl
viral
load
increas
figur
receiv
intraven
remdesivir
viral
load
alreadi
decreas
detect
threshold
whole
cours
diseas
two
patient
detect
rtpcr
neg
stool
serum
urin
ill
day
patient
whose
diseas
classifi
critic
posit
rtpcr
nasopharyng
sampl
bronchoalveolar
lavag
cycl
threshold
valu
e
gene
target
protocol
similar
cycl
threshold
valu
housekeep
gene
gapdh
respect
tabl
titr
nasopharynx
stabl
log
copi
per
cell
time
although
trend
toward
decreas
first
intraven
remdesivir
dose
thereaft
remdesivir
reiniti
figur
patient
rnaaemia
ill
day
subsequ
low
viral
load
detect
quantif
limit
cours
diseas
develop
pleural
exud
effus
detect
posit
pleural
fluid
neg
bacteri
cultur
figur
illustr
kinet
viral
load
nasopharyng
sampl
patient
diseas
onset
viral
load
decreas
time
becam
neg
ill
day
four
patient
patient
sever
ill
patient
patient
nasopharyng
viru
detect
persist
death
avail
sequenc
analysi
viru
patient
show
patient
compar
patient
correspond
two
distinct
event
import
patient
viru
cluster
virus
case
wuhan
shenzhen
china
california
usa
australia
taiwan
wherea
patient
viru
cluster
chongq
china
singapor
genet
epidemiolog
avail
onlin
furthermor
high
degre
ident
sequenc
patient
support
epidemiolog
link
case
likelihood
transmiss
case
seri
five
patient
illustr
three
differ
clinic
biolog
type
evolut
first
mild
case
two
paucisymptomat
patient
age
younger
year
diagnos
earli
high
viral
load
nasopharyng
sampl
suggest
signific
shed
reflect
viru
detect
rtpcr
second
two
young
patient
present
mild
symptom
admiss
experienc
secondari
progress
pneumonia
sever
diseas
day
third
older
patient
rapid
evolut
toward
critic
diseas
multipl
organ
failur
long
sustain
persist
nasopharyng
detect
associ
viral
rna
detect
multipl
site
includ
blood
among
five
case
investig
two
patient
mild
diseas
diagnos
earli
stage
diseas
contact
confirm
case
high
viral
load
upper
respiratori
tract
sampl
suggest
potenti
high
risk
transmiss
first
day
symptom
find
line
data
report
zou
colleagu
analys
viral
load
upper
respiratori
tract
relat
day
onset
symptom
symptomat
patient
higher
viral
load
detect
soon
symptom
onset
observ
suggest
viru
shed
pattern
patient
infect
differ
seen
sarscov
viru
load
low
diseas
onset
find
might
affect
implement
infect
control
measur
implic
control
measur
combin
immedi
isol
patient
diseas
togeth
blue
line
repres
viral
load
nasopharyng
swab
normalis
use
cell
quantif
posit
sampl
quantif
limit
repres
quantif
limit
line
readabl
neg
result
repres
xaxi
correspond
detect
limit
indic
done
indic
posit
result
indic
neg
resultnqnot
quantifi
titr
log
copi
per
g
stool
genet
epidemiolog
see
http
nextstrainorgncov
rapid
screen
monitor
contact
patient
detect
mild
symptom
two
five
patient
report
rna
detect
stool
sampl
possibl
rout
transmiss
must
investig
detect
viral
rna
necessarili
impli
infecti
particl
present
transmiss
particularli
patient
two
individu
diarrhoea
gastrointestin
symptom
case
seri
except
patient
critic
diseas
viral
load
decreas
time
becam
neg
ill
day
day
note
viru
also
detect
rtrtpcr
low
level
upper
respiratori
tract
even
full
resolut
symptom
whether
infecti
viru
might
still
present
despit
symptom
resolut
requir
attempt
viru
isol
uncertainti
justifi
european
centr
diseas
prevent
control
recommend
obtain
two
rtpcr
neg
nasopharyng
sampl
discharg
asymptomat
patient
conserv
recommend
howev
longer
feasibl
mani
european
countri
epidem
situat
case
seri
three
patient
sever
critic
diseas
two
differ
pattern
first
one
patient
sever
diseas
patient
characteris
biphas
evolut
start
mild
present
follow
secondari
respiratori
worsen
despit
decreas
viral
load
naso
pharyng
sampl
longer
detect
upper
respiratori
tract
one
patient
low
level
patient
pattern
ct
scan
moment
worsen
show
groundglass
lung
opac
line
report
other
patient
time
worsen
respiratori
symptom
around
day
diseas
onset
two
case
close
median
diseas
durat
worsen
day
iqr
previous
report
huang
collabor
patient
one
might
postul
th
e
lung
damag
relat
immuno
patholog
lesion
result
excess
proinflammatori
host
respons
rather
uncontrol
viral
replic
note
assess
viru
load
low
respiratori
tract
sampl
two
patient
second
pattern
observ
patient
classifi
critic
diseas
die
patient
consist
persist
high
viral
excret
upper
respiratori
tract
sampl
combin
posit
viru
detect
rtrtpcr
bodi
fluid
includ
blood
contrast
previou
pattern
persist
high
viral
load
suggest
abil
evad
immun
respons
inde
specul
shown
middl
east
respiratori
syndrom
mer
sar
coronaviru
infect
might
abl
inhibit
interferon
signal
pathway
result
higher
respiratori
viru
load
posit
viraemia
eventu
poor
prognosi
merscov
inde
patient
unlik
case
evid
high
viral
replic
respiratori
tract
evid
system
viru
dissemin
beyond
respiratori
tract
viru
detect
plasma
pleural
effus
fluid
impair
immun
respons
might
facilit
bacteri
fungal
superinfect
patient
similar
sever
pattern
sustain
viral
rna
respiratori
tract
detect
blood
also
report
china
report
previou
studi
sever
ill
patient
often
older
patient
comorbid
patient
age
year
might
impair
interferon
pathway
differ
pattern
especi
fact
patient
sever
critic
diseas
might
differ
viral
kinet
upper
respiratori
tract
might
import
find
suggest
differ
therapeut
approach
base
viral
kinet
monitor
might
need
patient
viru
load
decreas
upper
respiratori
tract
versu
high
viral
replic
system
viru
dissemin
cautiou
analys
data
small
number
patient
adapt
treatment
clinic
cours
consid
futur
studi
current
valid
antivir
treatment
control
infect
among
potenti
candid
remdesivir
antivir
prodrug
nucleosid
analogu
famili
broadspectrum
invitro
invivo
activ
numer
rna
virus
includ
anim
model
compar
lopinavir
plu
ritonavir
combin
interferon
beta
two
potenti
candid
remdesivir
significantli
reduc
viru
titr
mice
infect
merscov
decreas
lung
tissu
damag
remdesivir
treatment
improv
diseas
outcom
reduc
viral
load
sarscovinfect
mice
inhibitori
vitro
phase
clinic
trial
assess
drug
treatment
ebola
viru
infect
therefor
data
exist
safeti
use
human
henc
basi
expert
opinion
consid
remdesivir
use
three
patient
sever
diseas
pattern
best
knowledg
one
case
remdesivir
use
report
far
two
randomis
control
trial
enrol
patient
china
assess
clinic
benefit
treatment
basi
data
draw
conclus
potenti
efficaci
remdesivir
infect
two
patient
drug
initi
time
diseas
worsen
viru
alreadi
bare
detect
clinic
specimen
one
remdesivir
discontinu
day
combin
alanin
aminotransferas
elev
rash
although
could
confirm
advers
event
relat
remdesivir
third
patient
remdesivir
discontinu
singl
dose
renal
replac
therapi
avoid
risk
cyclodextrin
accumul
remdesivir
contain
cyclodextrin
excipi
whose
clearanc
linearli
relat
creatinin
clearanc
patient
condit
worsen
viral
load
decreas
reiniti
remdesivir
paper
report
clinic
virolog
data
first
case
europ
although
acknowledg
fact
result
provid
base
small
number
case
detail
comprehens
sampl
strategi
enabl
us
illustr
differ
cours
diseas
observ
provid
relev
criteria
regard
sever
diseas
believ
find
contribut
better
understand
natur
histori
diseas
contribut
advanc
implement
effici
infect
control
strategi
fm
consult
novarti
ipsen
servier
da
volterra
receiv
research
grant
roch
sanofi
outsid
submit
work
jcl
receiv
lectur
fee
merck
sharp
dohm
research
grant
anio
outsid
submit
work
dd
serv
advisori
board
gileadsci
viivhealthcar
janssencilag
merck
sharp
dohm
outsid
submit
work
dm
serv
advisori
board
gilead
sigma
tau
outsid
submit
work
jft
serv
advisori
board
gilead
pfizer
merck
bayer
menarini
paratek
medimmun
outsid
submit
work
receiv
research
grant
merck
astella
outsid
submit
work
receiv
lectur
fee
pfizer
merck
gilead
outsid
submit
work
bl
cochair
global
influenza
respiratori
syncyti
viru
initi
chair
scientif
committe
global
hospit
influenza
surveil
network
member
foundat
influenza
receiv
person
remuner
activ
receiv
travel
grant
attend
meet
abbott
seegen
sanofi
sdvw
member
european
scientif
work
group
influenza
scientif
advisori
council
global
initi
share
influenza
data
lectur
sanofi
outsid
submit
work
receiv
person
remuner
activ
author
declar
compet
interest
